This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
JMPDP-027 cyclic peptide blocked PD-1/PD-L1 with EC50 of 5.9 nM (comparable to pembrolizumab) and showed potent in vivo anticancer activity.
Why it matters
Antibody checkpoint inhibitors revolutionized cancer treatment but are expensive. Peptide alternatives could make immunotherapy more accessible.
The numbers in context
EC50 5.9 nM; comparable to pembrolizumab; serum stable; no toxicity; in vivo efficacy ≈ anti-PD-L1 mAb
How the study worked
Rational design and optimization of macrocyclic peptide. T cell restoration assay, serum stability, cytotoxicity, and CT26 colon carcinoma mouse model.
Who was studied
CT26 colon carcinoma mouse model
What this study cannot tell us
Single mouse tumor model. Manufacturing scalability not demonstrated. Long-term pharmacokinetics and safety unknown. Head-to-head with pembrolizumab not done in vivo.
Read the original research
Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein-protein interaction.
RSC advances, 11(38), 23270-23279
Citation
Miao, Qi; Zhang, Wanheng; Zhang, Kuojun; Li, He; Zhu, Jidong; Jiang, Sheng. (2021). Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein-protein interaction.. RSC advances, 11(38), 23270-23279. https://doi.org/10.1039/d1ra03118j